Dipexium Pharmaceuticals, a late-stage biotech developing a topical antibiotic for diabetic foot ulcer infections, raised $33 million by offering 2.8 million shares (upsized from 2.3 million) at $12, the low end of the $12 to $14 range. Dipexium Pharmaceuticals will list on the NASDAQ under the symbol DPRX. Oppenheimer & Co. acted as sole bookrunner on the deal.
